FDA Clears Oral Version of Wegovy, Expanding Access to GLP-1 Obesity Treatments
Novo Nordisk’s daily semaglutide tablet offers an alternative to injectables as competition intensifies in the weight-loss drug market The US […]
GLP-1-OBESITY-TREATMENT
WHO’s GLP-1 Obesity Guideline Opens Major Growth Avenues for the Global Pharma Industry
The World Health Organisation (WHO) has issued its first global guideline on the use of GLP-1 receptor agonists for treating […]
